Short- and long-term estrogen deprivation of T47D human breast cancer cells in culture

doi:10.1016/0277-5379(89)90348-9

European Journal of Cancer and Clinical Oncology

Volume 25, Issue 12, December 1989, Pages 1777-1788

https://doi.org/10.1016/0277-5379(89)90348-9 Get rights and content

Abstract

The effects of short- and long-term estrogen deprivation on T47D human breast cancer cells was studied. Cells were routinely grown in an estrogenized environment in media containing fetal bovine serum with phenol red indicator. Cells were estrogen deprived (grown in media containing dextran-coated charcoal-stripped fetal bovine serum without phenol red) for either 10 days or at least 8 months, and effects on genotype, receptor content, and cell growth responsiveness were studied. Cells grown in an estrogenized environment are hypertetraploid, whereas long-term estrogen-deprived cells have become hyperdiploid. Short-term estrogen-deprived cells exhibit a decreased growth rate and progesterone receptor (PgR) content, while estrogen receptor (ER) content is not significantly altered. ER mRNA levels are significantly decreased in these cells. Incubation of these cells with estradiol (10⁻¹⁰ M) for 6 days causes a 5-fold stimulation in cell growth and this stimulation can be inhibited by the antiestrogens 4-hydroxytamoxifen (4-OHT), ICI 164,384, and RU 39411.

Cells cultured under long-term estrogen deprivation exhibited an increased growth rate and were refractory to the effects of estradiol and of 4-OHT on cell growth. These cells were ER negative with low levels of PgR; however, one clone of this line was found to be ER and PgR negative. No mRNA for the ER was detected in this line or its clone. With these cell lines it is possible to study the biological characteristics necessary for the outgrowth of a receptor negative, hormone nonresponsive cell population from a receptor positive, hormone-responsive population grown in a estrogen-free environment.

References (33)

I Keydar et al.
Establishment and characterization of a cell line of human breast carcinoma origin
Eur J Cancer
(1979)
WV Welshons et al.
Estrogenic activity of phenol red
Mol Cell Endocrinol
(1988)
RD Bindal et al.
Lipophilic impurities, not phenolsulfonphthalein, account for the estrogenic activity in commercial preparations of phenol red
J Steroid Biochem
(1988)
WV Welshons et al.
Adaptation of estrogen-dependent MCF-7 cells to low estrogen (phenol red-free) culture
Eur J Cancer Clin Oncol
(1987)
KB Horwitz
Is a functional estrogen receptor always required for progesterone receptor induction in breast cancer?
J Steroid Biochem
(1981)
KB Horwitz et al.
Variant T47D human breast cancer cells with high progesterone-receptor levels despite estrogen and antiestrogen resistance
Cell
(1982)
MB Mockus et al.
Progesterone receptors in human breast cancer
J Biol Chem
(1983)
D Chalbos et al.
Dual effects of the progestin R5020 on proteins released by the T47D human breast cancer cells
J Biol Chem
(1984)
LG Kral et al.
Quantitative determinations of nuclear estrogen receptors by an enzyme immunoassay: applicability and caveats
J Steroid Biochem
(1988)
BJ Dolnick et al.
5-Fluorouracil modulation of dihydrofolate reductase RNA levels in methotrexate-resistant cells
J Biol Chem
(1983)

C LaBarca et al.

A simple, rapid, and sensitive DNA assay procedure

Anal Biochem

(1980)

MM Bradford

A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding

Anal Biochem

(1976)

BR Westley et al.

Oestrogen regulates oestrogen receptor mRNA levels in an oestrogen-responsive human breast cancer cell line

Biochem Biophys Res Commun

(1988)

MD Soule et al.

A human cell line from a pleural effusion derived from a breast carcinoma

J Natl Cancer Inst

(1973)

ME Lippman et al.

Oestrogen-responsive human breast cancer in long term tissue culture

Nature

(1975)

ME Lippman et al.

The effects of estrogens and antiestrogens on hormone-responsive human breast cancer in long-term tissue culture

Cancer Res

(1976)

Cited by (54)

Estrogen receptor-dependent regulation of CYP2B6 in human breast cancer cells
2010, Biochimica et Biophysica Acta - Gene Regulatory Mechanisms
Estrogen receptor α (ERα) mediates the biological actions of estrogens and also contributes to the development and progression of breast cancer. To gain a more comprehensive understanding of ERα-mediated transcription, we used chromatin immunoprecipitation and promoter focused microarrays (ChIP-chip) to identify ERα binding sites in T-47D human breast cancer cells. Transcription factor binding site analysis revealed that the estrogen response element (ERE) was significantly over-represented and was found in 50% of the 243 ERα-bound regions identified. Interestingly, multiple ERα-bound regions were detected in the upstream regulatory sequences of the CYP2B gene cluster. Because ERα has been reported to regulate the expression of other cytochrome P450 enzymes and CYP2B6 is highly expressed in ERα-positive breast tumors, we focused on characterizing the ERα-dependent regulation of CYP2B6. Reporter gene assays revealed that ERα and ERβ increased CYP2B6-regulated gene expression through a functional ERE located at −1669 to −1657 in the upstream regulatory region of CYP2B6. E2 increased ERα and nuclear receptor coactivator 3 (NCoA3) recruitment to the 5′-flanking region of CYP2B6, and increased CYP2B6 mRNA levels in T-47D but not in MCF-7 human breast cancer cells. RNAi-mediated knockdown of ERα in the T-47D cells resulted in a significant decrease in CYP2B6 mRNA levels. Taken together, our study provides evidence for cell-type specific transcriptional regulation of the CYP2B6 gene by ERs.
Use of global gene expression patterns in mechanistic studies of oestrogen action in MCF7 human breast cancer cells
2009, Journal of Steroid Biochemistry and Molecular Biology
Over the years, the MCF7 human breast cancer cell line has provided a model system for the study of cellular and molecular mechanisms in oestrogen regulation of cell proliferation and in progression to oestrogen and antioestrogen independent growth. Global gene expression profiling has shown that oestrogen action in MCF7 cells involves the coordinated regulation of hundreds of genes across a wide range of functional groupings and that more genes are downregulated than upregulated. Adaptation to long-term oestrogen deprivation, which results in loss of oestrogen-responsive growth, involves alterations to gene patterns not only at early time points (0–4 weeks) but continuing through to later times (20–55 weeks), and even involves alterations to patterns of oestrogen-regulated gene expression. Only 48% of the genes which were regulated ≥2-fold by oestradiol in oestrogen-responsive cells retained this responsiveness after long-term oestrogen deprivation but other genes developed de novo oestrogen regulation. Long-term exposure to fulvestrant, which resulted in loss of growth inhibition by the antioestrogen, resulted in some very large fold changes in gene expression up to 10,000-fold. Comparison of gene profiles produced by environmental chemicals with oestrogenic properties showed that each ligand gave its own unique expression profile which suggests that environmental oestrogens entering the human breast may give rise to a more complex web of interference in cell function than simply mimicking oestrogen action at inappropriate times.
New insights into the metabolism of tamoxifen and its role in the treatment and prevention of breast cancer
2007, Steroids
The metabolism of tamoxifen is being redefined in the light of several important pharmacological observations. Recent studies have identified 4-hydroxy N-desmethyltamoxifen (endoxifen) as an important metabolite of tamoxifen necessary for antitumor actions. The metabolite is formed through the enzymatic product of CYP2D6 which also interacts with specific selective serotonin reuptake inhibitors (SSRIs) used to prevent the hot flashes observed in up to 45% of patients taking tamoxifen. Additionally, the finding that enzyme variants of CYP2D6 do not promote the metabolism of tamoxifen to endoxifen means that significant numbers of women might not receive optimal benefit from tamoxifen treatment. Clearly these are particularly important issues not only for breast cancer treatment but also for selecting premenopausal women, at high risk for breast cancer, as candidates for chemoprevention using tamoxifen.
Exploiting the apoptotic actions of oestrogen to reverse antihormonal drug resistance in oestrogen receptor positive breast cancer patients
2007, Breast
The ubiquitous application of selective oestrogen receptor modulators (SERMs) and aromatase inhibitors for the treatment and prevention of breast cancer has created a significant advance in patient care. However, the consequence of prolonged treatment with antihormonal therapy is the development of drug resistance. Nevertheless, the systematic description of models of drug resistance to SERMs and aromatase inhibitors has resulted in the discovery of a vulnerability in tumour homeostasis that can be exploited to improve patient care. Drug resistance to antihormones evolves, so that eventually the cells change to create novel signal transduction pathways for enhanced oestrogen (GPR30+OER) sensitivity, a reduction in progesterone receptor production and an increased metastatic potential. Most importantly, antihormone resistant breast cancer cells adapt with an ability to undergo apoptosis with low concentrations of oestrogen. The oestrogen destroys antihormone resistant cells and reactivates sensitivity to prolonged antihormonal therapy. We have initiated a major collaborative program of genomics and proteomics to use our laboratory models to map the mechanism of subcellular survival and apoptosis in breast cancer. The laboratory program is integrated with a clinical program that seeks to determine the minimum dose of oestrogen necessary to create objective responses in patients who have succeeded and failed two consecutive antihormonal therapies. Once our program is complete, the new knowledge will be available to translate to clinical care for the long-term maintenance of patients on antihormone therapy.
Changes in oestrogen receptor-α and -β during progression to acquired resistance to tamoxifen and fulvestrant (Faslodex, ICI 182,780) in MCF7 human breast cancer cells
2006, Journal of Steroid Biochemistry and Molecular Biology
Citation Excerpt :
Growth of oestrogen responsive human breast cancer cells in the long-term absence of oestrogen results in an initial phase of slow growth but this is followed by upregulation of growth such that the cells eventually grow at the same rate in the absence of oestrogen as they originally grew only in the presence of oestrogen [8–15]. Only one report has documented loss of ER in this process [16]. In most models, ER are not lost and remain functional in that oestrogen-regulated genes such as pS2 or progesterone receptor are still increased by the readdition of oestradiol [8,10–15].
Cell culture models of antioestrogen resistance often involve applying selective pressures of oestrogen deprivation simultaneously with addition of tamoxifen or fulvestrant (Faslodex, ICI 182,780) which makes it difficult to distinguish events in development of antioestrogen resistance from those in loss of response to oestrogen or other components. We describe here time courses of loss of antioestrogen response using either oestrogen-maintained or oestrogen-deprived MCF7 cells in which the only alteration to the culture medium was addition of 10⁻⁶ M tamoxifen or 10⁻⁷ M fulvestrant. In both oestrogen-maintained and oestrogen-deprived models, loss of growth response to tamoxifen was not associated with loss of response to fulvestrant. However, loss of growth response to fulvestrant was associated in both models with concomitant loss of growth response to tamoxifen. Measurement of oestrogen receptor alpha (ERα) and oestrogen receptor beta (ERβ) mRNA by real-time RT-PCR together with ERα and ERβ protein by Western immunoblotting revealed substantial changes to ERα levels but very little alteration to ERβ levels following development of antioestrogen resistance. In oestrogen-maintained cells, tamoxifen resistance was associated with raised levels of ERα mRNA/protein. However by contrast, in oestrogen-deprived MCF7 cells, where oestrogen deprivation alone had already resulted in increased levels of ERα mRNA/protein, long-term tamoxifen exposure now reduced ERα levels. Whilst long-term exposure to fulvestrant reduced ERα mRNA/protein levels in the oestrogen-maintained cells to a level barely detectable by Western immunoblotting and non-functional in inducing gene expression (ERE-LUC reporter or pS2), in oestrogen-deprived cells the reduction was much less substantial and these cells retained an oestrogen-induction of both the ERE-LUC reporter gene and the endogenous pS2 gene which could still be inhibited by antioestrogen. This demonstrates that whilst ERα can be abrogated by fulvestrant and increased by tamoxifen in some circumstances, this does not always hold true and mechanisms other than alteration to ER must be involved in the development of antioestrogen resistant growth.
Endocrine resistance and breast cancer plasticity are controlled by CoREST
2022, Nature Structural and Molecular Biology

View all citing articles on Scopus

^☆: These studies were supported by NIH grant CA 32713 and Cancer Center Core grant P30-CA14520. CSM was supported by NIH grant CA09471.

View full text

Short- and long-term estrogen deprivation of T47D human breast cancer cells in culture☆

Abstract

Eur J Cancer

Mol Cell Endocrinol

J Steroid Biochem

Eur J Cancer Clin Oncol

J Steroid Biochem

Cell

J Biol Chem

J Biol Chem

J Steroid Biochem

J Biol Chem

Anal Biochem

Anal Biochem

Biochem Biophys Res Commun

A human cell line from a pleural effusion derived from a breast carcinoma

J Natl Cancer Inst

Oestrogen-responsive human breast cancer in long term tissue culture

Nature

The effects of estrogens and antiestrogens on hormone-responsive human breast cancer in long-term tissue culture

Cancer Res